VELA Investment Management LLC Buys 7,606 Shares of Zoetis Inc. $ZTS

VELA Investment Management LLC lifted its stake in Zoetis Inc. (NYSE:ZTS) by 49.0% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 23,134 shares of the company’s stock after buying an additional 7,606 shares during the period. VELA Investment Management LLC’s holdings in Zoetis were worth $1,662,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. Hohimer Wealth Management LLC bought a new position in Zoetis during the 2nd quarter worth approximately $4,012,000. Tema ETFs LLC increased its stake in Zoetis by 18.9% in the 2nd quarter. Tema ETFs LLC now owns 8,984 shares of the company’s stock worth $646,000 after purchasing an additional 1,431 shares during the period. Handelsbanken Fonder AB lifted its position in Zoetis by 10.7% in the second quarter. Handelsbanken Fonder AB now owns 228,467 shares of the company’s stock valued at $16,418,000 after purchasing an additional 21,990 shares during the last quarter. Fulton Bank N.A. boosted its stake in shares of Zoetis by 6.1% during the second quarter. Fulton Bank N.A. now owns 11,366 shares of the company’s stock valued at $817,000 after purchasing an additional 652 shares during the period. Finally, Wealthcare Capital Partners LLC boosted its stake in shares of Zoetis by 97.4% during the second quarter. Wealthcare Capital Partners LLC now owns 4,195 shares of the company’s stock valued at $301,000 after purchasing an additional 2,070 shares during the period. Institutional investors own 92.80% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on the stock. UBS Group cut their target price on shares of Zoetis from $85.00 to $80.00 and set a “neutral” rating on the stock in a report on Friday, August 7th. Citigroup dropped their price target on shares of Zoetis from $112.00 to $96.00 and set a “buy” rating for the company in a research report on Tuesday. BNP Paribas Exane cut their price target on shares of Zoetis from $146.00 to $110.00 and set an “outperform” rating on the stock in a report on Tuesday. Barclays cut their price target on shares of Zoetis from $136.00 to $85.00 and set an “equal weight” rating on the stock in a report on Wednesday, July 1st. Finally, TD Cowen lowered their price objective on shares of Zoetis from $150.00 to $104.00 and set a “buy” rating for the company in a research note on Tuesday, June 30th. Eight equities research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $109.62.

Zoetis Price Performance

ZTS opened at $73.64 on Friday. The company has a debt-to-equity ratio of 2.87, a quick ratio of 1.84 and a current ratio of 3.08. Zoetis Inc. has a 52-week low of $71.45 and a 52-week high of $160.48. The stock has a market capitalization of $30.43 billion, a PE ratio of 12.13, a price-to-earnings-growth ratio of 1.31 and a beta of 0.74. The stock’s 50 day moving average price is $76.30 and its 200-day moving average price is $99.01.

Zoetis (NYSE:ZTS) last announced its earnings results on Thursday, August 6th. The company reported $1.87 EPS for the quarter, beating analysts’ consensus estimates of $1.85 by $0.02. Zoetis had a return on equity of 74.89% and a net margin of 27.49%.The company had revenue of $2.47 billion during the quarter, compared to the consensus estimate of $2.50 billion. During the same quarter in the prior year, the company earned $1.76 earnings per share. The firm’s revenue for the quarter was down .2% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. On average, equities research analysts predict that Zoetis Inc. will post 6.19 EPS for the current year.

Zoetis Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Monday, July 20th will be issued a $0.53 dividend. The ex-dividend date is Monday, July 20th. This represents a $2.12 annualized dividend and a yield of 2.9%. Zoetis’s dividend payout ratio is 34.93%.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.